Wang Sheng-Min, Han Changsu, Lee Soo-Jung, Jun Tae-Youn, Patkar Ashwin A, Masand Prakash S, Pae Chi-Un
a Department of Psychiatry , The Catholic University of Korea College of Medicine , Seoul , Republic of Korea.
b International Health Care Center, Seoul St. Mary's Hospital, College of Medicine , The Catholic University of Korea , Seoul , Republic of Korea.
Expert Opin Investig Drugs. 2017 Jun;26(6):687-698. doi: 10.1080/13543784.2017.1323870. Epub 2017 May 12.
Schizophrenia is a debilitating illness with a chronic impact on social function and daily living. Although various antipsychotics are available, there are still many challenges and unmet needs. Thus, many compounds with diverse mechanisms have been investigated, but all approved antipsychotics still require interactions with dopamine D receptors. Areas covered: We searched for investigational drugs using the key words 'dopamine' and 'schizophrenia' in American and European clinical trial registers (clinicaltrials.gov; clinicaltrialsregister.eu). Published articles were searched in PubMed, Embase, Medline, PsycINFO, Cumulative Index to Nursing and Allied Health Literature (CINAHL), the Web of Science and the Cochrane Central Register of Controlled Trials Library. Expert opinion: The prospect of developing a dopamine antagonist is hopeful. Brexpiprazole and cariprazine, which were agents listed as 'investigational dopamine antagonists,' just received FDA approval. Novel agents such as BL 1020, ITI-007, and JNJ-37822681 have solid published data available, and agents such as L-THP, Lu AF35700, S33138, and SB-773812 are under vigorous investigation. However, the expected benefits of the newly developed antagonists may not be great because they offer little enhanced efficacy for negative symptoms, cognition and functional outcomes.
精神分裂症是一种使人衰弱的疾病，对社会功能和日常生活有长期影响。尽管有多种抗精神病药物可供使用，但仍存在许多挑战和未满足的需求。因此，人们对许多具有不同作用机制的化合物进行了研究，但所有已获批的抗精神病药物仍需要与多巴胺D受体相互作用。涵盖领域：我们在美国和欧洲临床试验注册库（clinicaltrials.gov；clinicaltrialsregister.eu）中使用关键词“多巴胺”和“精神分裂症”搜索了研究药物。在PubMed、Embase、Medline、PsycINFO、护理及相关健康文献累积索引（CINAHL）、科学网和Cochrane对照试验中央注册库图书馆中搜索了已发表的文章。专家观点：开发多巴胺拮抗剂的前景是有希望的。被列为“研究性多巴胺拮抗剂”的药物布雷哌唑和卡立哌嗪刚刚获得美国食品药品监督管理局（FDA）的批准。诸如BL 1020、ITI - 007和JNJ - 37822681等新型药物已有可靠的发表数据，而诸如左旋四氢巴马汀、Lu AF35700、S33138和SB - 773812等药物正在大力研究中。然而，新开发的拮抗剂预期的益处可能不大，因为它们对阴性症状、认知和功能结局几乎没有增强疗效。
